Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 2, 2004, Pages 104-112

  Yu, Kyung Sang ^a   Cho, Joo Youn ^a   Jang, In Jin ^a   Hong, Kyoung Seop ^a   Chung, Jae Yong ^a   Kim, Jung Ryul ^a   Lim, Hyeong Seok ^a   Oh, Dal Seok ^a   Yi, So Young ^a   Liu, Kwang Hyeon ^b   Shin, Jae Gook ^b   Shin, Sang Goo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; HYDROXYL GROUP; ITRACONAZOLE; MIDAZOLAM; RIFAMPICIN;

ACETYLATOR PHENOTYPE; ARTICLE; ASIAN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; KOREA; NORMAL HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; WILD TYPE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; INFUSIONS, INTRAVENOUS; ITRACONAZOLE; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RIFAMPIN; SENSITIVITY AND SPECIFICITY; VARIATION (GENETICS);

EID: 3542998143     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.03.009     Document Type: Article

References (30)

1. Ekins S., Stresser D.M., Williams J.A. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci. 24:2003;161-166
2. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., Watkins P.B. The human CYP3A subfamily practical considerations. Drug Metab Rev. 32:2000;339-361
3. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 27:2001;383-391
4. Hustert E., Haberl M., Burk O., Wolbold R., He Y.Q., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 11:2001;773-779
5. Lin Y.S., Dowling A.L., Quigley S.D., Farin F.M., Zhang J., Lamba J., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 62:2002;162-172
6. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 30:2002;883-891
7. Williams J.A., Cook J., Hurst S.I. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos. 31:2003;1526-1530
8. Patki K.C., Von Moltke L.L., Greenblatt D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450 role of cyp3a4 and cyp3a5. Drug Metab Dispos. 31:2003;938-944
9. von Moltke L.L., Greenblatt D.J., Schmider J., Duan S.X., Wright C.E., Harmatz J.S., et al. Midazolam hydroxylation by human liver microsomes in vitro inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol. 36:1996;783-791
10. Wandel C., Bocker R., Bohrer H., Browne A., Rugheimer E., Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth. 73:1994;658-661
11. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994 29;47:1643-53
12. Backman J.T., Kivisto K.T., Olkkola K.T., Neuvonen P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 54:1998;53-58
13. Fukuen S., Fukuda T., Maune H., Ikenaga Y., Yamamoto I., Inaba T., et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and*6, in a Japanese population. Pharmacogenetics. 12:2002;331-334
14. Kashuba A.D., Bertino J.S. Jr, Rocci M.L. Jr, Kulawy R.W., Beck D.J., Nafziger A.N. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther. 64:1998;269-277
15. Paulussen A., Lavrijsen K., Bohets H., Hendrickx J., Verhasselt P., Luyten W., et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics. 10:2000;415-424
16. Hiratsuka M., Takekuma Y., Endo N., Narahara K., Hamdy S.I., Kishikawa Y., et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol. 58:2002;417-421
17. Shih P.S., Huang J.D. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos. 30:2002;1491-1496
18. Balram C., Zhou Q., Cheung Y.B., Lee E.J. CYP3A5*3 and*6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol. 59:2003;123-126
19. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 54:2002;1271-1294
20. Floyd M.D., Gervasini G., Masica A.L., Mayo G., George A.L. Jr, Bhat K., et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 13:2003;595-606
21. Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 41:2002;329-342
22. Cummins C.L., Wu C.Y., Benet L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther. 72:2002;474-489
23. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 16:1999;408-414
24. Thummel K.E., O'Shea D., Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 59:1996;491-502
25. Holazo A.A., Winkler M.B., Patel I.H. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol. 28:1988;1040-1045
26. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 38:2000;41-57
27. Gibbs M.A., Thummel K.E., Shen D.D., Kunze K.L. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos. 27:1999;180-187
28. Eeckhoudt S.L., Desager J.P., Robert A.R., Leclercq I., Verbeeck R.K., Horsmans Y. Midazolam and cortisol metabolism before and after CYP3A induction in humans. Int J Clin Pharmacol Ther. 39:2001;293-299
29. Rae J.M., Johnson M.D., Lippman M.E., Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 299:2001;849-857
30. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Effects of the antifungal agents on oxidative drug metabolism clinical relevance. Clin Pharmacokinet. 38:2000;111-180